EKF Diagnostics Holdings plc
("EKF" or the "Company")
Posting of Annual Report & Accounts
and
Notice of Annual General Meeting
EKF (AIM: EKF), the AIM-listed global diagnostics business, confirms that the Annual Report and Accounts for the year ended 31 December 2021 ("2021 Annual Report") and the Notice of the 2022 Annual General Meeting ("AGM") have now been published on the Company's website here.
The 2021 Annual Report, the Notice of AGM and details for voting by proxy will be posted to shareholders who have not consented to receive electronic communications today, on 25 April 2022.
The AGM is to be held at 11:00 am on 18 May 2022 at 6 Stratton Street Mayfair, London W1J 8LD and will consider the Resolutions set out in the Notice of AGM.
The Company is providing a facility for shareholders to listen in to the AGM either online or telephonically (in a non-voting capacity) and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Directors would request that shareholders register for the meeting and submit questions in advance, before 11:00 am on 17 May 2022. To register for dial-in details and to submit any questions please contact Walbrook PR via email at ekf@walbrookpr.com or call +44 (0)20 7933 8787.
Proxy voting
Shareholders will not receive a hard copy form of proxy for the 2022 AGM in the post. Instead, Shareholders will be able to vote electronically using the link www.signalshares.com. Proxy votes must be received no later than 11:00 am on 16 May 2022.
Shareholders may request a hard copy form of proxy directly from the Registrars, Link Group, on Tel: 0371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales.
|
EKF Diagnostics Holdings plc |
||
|
Mike Salter, CEO |
Tel: +44 (0)29 2071 0570 |
|
|
Marc Davies, CFO |
|
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) |
Tel: +44 (0)20 7496 3000 |
|
|
Aubrey Powell / George Tzimas / Tom Salvesen |
|
|
|
|
|
|
|
Investec Bank plc (Joint Broker) |
Tel: +44 (0)20 7597 4000 |
|
|
Gary Clarence / Daniel Adams / Ben Farrow |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
|
|
Paul McManus / Lianne Applegarth |
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 |
|
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:
|
Point-of-Care |
Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.
|
|
Central Laboratory |
Clinical chemistry, Small lab analysers, Centrifuges Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycated Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin
|
|
Life Sciences |
Enzyme fermentation, Custom products and Bulk fermentation
|
|
Contract Manufacturing |
Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits
|
|
Laboratory Services |
In September 2021, EKF completed the acquisition of Advanced Diagnostic Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. The laboratory provides testing for a variety of clinical, forensic and microbiological sample types using a range of analytical techniques. This acquisition positions EKF as a leading 'one stop' provider of diagnostic products and services from sample collection to results. |
In May 2021, EKF announced its strategy for delivering growth to 2024 and beyond, and continuing to deliver shareholder value. The strategy for growth can be summarised as:
|
• |
continuing innovation in products and services in Point-of-Care, Central Laboratory and Life Sciences leveraging new and existing routes to market and relationships; |
|
• |
investment in expanded production and kitting capabilities to offer a suite of diagnostic Contract Manufacturing solutions to third party businesses; |
|
• |
expansion of CLIA Laboratories Testing offering, building on the acquired capabilities in ADL Health; and |
|
• |
identify complementary earnings-enhancing acquisitions with key strategic value. |
EKF will also continue to generate enhanced shareholder value through:
|
• |
a progressive dividend policy; and |
|
• |
its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us advanced access to innovative commercial opportunities and where we can build on the ongoing successes of Renalytix plc, Verici Dx plc and Trellus Health plc.
|